JAMA
Original Investigation
April 8, 2024
Steven E. Nissen, MD; Kathy Wolski, MPH; Gerald F. Watts, MD, DSc; Michael J. Koren, MD; Henry Fok, MBBS, PhD; Stephen J. Nicholls, MBBS, PhD; David ´¡.ÌýRider, PhD; Leslie Cho, MD; Steven Romano, MD; Carrie Melgaard, MS; Curtis Rambaran, MBBS, MD
JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.